Tag: IND
StemCyte Receives IND Clearance Of Mononuclear Stem Cells In Spinal Cord Injury Clinical Trials
On December 14, 2018, the U.S. Food and Drug Administration
(FDA), approved StemCyte’s Phase II Investigational New Drug (IND) application
for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood
Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord
injury. Founded in 1997,...
